KR20160055911A - 조합 약물 요법 - Google Patents

조합 약물 요법 Download PDF

Info

Publication number
KR20160055911A
KR20160055911A KR1020167009965A KR20167009965A KR20160055911A KR 20160055911 A KR20160055911 A KR 20160055911A KR 1020167009965 A KR1020167009965 A KR 1020167009965A KR 20167009965 A KR20167009965 A KR 20167009965A KR 20160055911 A KR20160055911 A KR 20160055911A
Authority
KR
South Korea
Prior art keywords
compound
cancer
methyl
administered
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167009965A
Other languages
English (en)
Korean (ko)
Inventor
조엘 그레스호크
커티스 얼 바크만
사무엘 찰스 블랙만
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20160055911A publication Critical patent/KR20160055911A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167009965A 2013-09-19 2014-09-16 조합 약물 요법 Ceased KR20160055911A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361879895P 2013-09-19 2013-09-19
US61/879,895 2013-09-19
PCT/US2014/055816 WO2015042029A1 (en) 2013-09-19 2014-09-16 Combination drug therapy

Publications (1)

Publication Number Publication Date
KR20160055911A true KR20160055911A (ko) 2016-05-18

Family

ID=52689320

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167009965A Ceased KR20160055911A (ko) 2013-09-19 2014-09-16 조합 약물 요법

Country Status (10)

Country Link
US (1) US20160228446A1 (enExample)
EP (1) EP3046556A4 (enExample)
JP (3) JP6346944B2 (enExample)
KR (1) KR20160055911A (enExample)
CN (1) CN105530934A (enExample)
AU (1) AU2014321456B2 (enExample)
BR (1) BR112016005000A8 (enExample)
CA (1) CA2921156A1 (enExample)
RU (1) RU2016110546A (enExample)
WO (1) WO2015042029A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6346944B2 (ja) * 2013-09-19 2018-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法
US10206949B2 (en) 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US20210393651A1 (en) * 2018-11-09 2021-12-23 Dana-Farber Cancer Institute, Inc. Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
NZ564223A (en) * 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
AU2007212447B2 (en) * 2006-02-03 2013-02-21 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
BRPI0709771B1 (pt) * 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
RU2554081C2 (ru) * 2010-02-24 2015-06-27 Медивэйшн Простейт Терапьютикс, Инк. Способ синтеза соединений диарилтиогидантоина и диарилгидантоина
KR101594002B1 (ko) * 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
US20150342957A1 (en) * 2013-01-09 2015-12-03 Glaxosmithkline Intellectual Property (No.2) Limited Combination
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
JP6346944B2 (ja) * 2013-09-19 2018-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法

Also Published As

Publication number Publication date
JP6563558B2 (ja) 2019-08-21
AU2014321456A1 (en) 2016-03-10
CN105530934A (zh) 2016-04-27
AU2014321456B2 (en) 2018-05-24
RU2016110546A (ru) 2017-10-24
WO2015042029A1 (en) 2015-03-26
JP6346944B2 (ja) 2018-06-20
JP2019196391A (ja) 2019-11-14
JP2016530208A (ja) 2016-09-29
RU2016110546A3 (enExample) 2018-03-20
US20160228446A1 (en) 2016-08-11
EP3046556A4 (en) 2017-04-26
CA2921156A1 (en) 2015-03-26
BR112016005000A8 (pt) 2018-01-23
EP3046556A1 (en) 2016-07-27
JP2018158930A (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
AU2010306653B2 (en) Combination
US8906910B2 (en) Imidazopyridine derivatives as PI3 kinase
US8778937B2 (en) Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
US20160367662A1 (en) Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
US20150273057A1 (en) Combination
JP6355724B2 (ja) がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
JP6563558B2 (ja) 組み合わせ薬物療法
JP2021155446A (ja) 組合せ物
WO2008132121A1 (en) Lh-indazole-3-amine compounds as ikk1 inhibitors
US20170348329A1 (en) Combination Drug Therapy
HK40081897B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40106558B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40081897A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40106558A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
US20150352121A1 (en) Combination
HK1181971B (en) Benzimidazole derivatives as pi3 kinase inhibitors
HK1181971A (en) Benzimidazole derivatives as pi3 kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160415

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190618

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200831

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201123

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200831

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I